Berenberg Bank Analysts Give Gilead Sciences, Inc. (GILD) a $78.00 Price Target

Gilead Sciences, Inc. (NASDAQ:GILD) has been assigned a $78.00 price objective by equities research analysts at Berenberg Bank in a report issued on Tuesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Berenberg Bank’s target price points to a potential upside of 11.75% from the company’s previous close.

Other analysts also recently issued reports about the company. Citigroup Inc. increased their target price on Gilead Sciences to $87.00 in a research note on Thursday, January 26th. RBC Capital Markets cut their target price on Gilead Sciences to $75.00 in a research note on Wednesday, February 8th. Jefferies Group LLC increased their target price on Gilead Sciences from $93.00 to $95.00 and gave the company a “buy” rating in a research note on Tuesday, October 25th. Cowen and Company set a $120.00 target price on Gilead Sciences and gave the company a “buy” rating in a research note on Sunday, October 23rd. Finally, Piper Jaffray Companies set a $108.00 target price on Gilead Sciences and gave the company a “buy” rating in a research note on Thursday, October 20th. One analyst has rated the stock with a sell rating, eleven have given a hold rating, fifteen have assigned a buy rating and two have given a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $87.20.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD) opened at 69.80 on Tuesday. Gilead Sciences has a 12 month low of $65.38 and a 12 month high of $103.10. The stock’s 50 day moving average price is $71.83 and its 200-day moving average price is $75.40. The company has a market capitalization of $91.44 billion, a P/E ratio of 7.02 and a beta of 1.11.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 7th. The biopharmaceutical company reported $2.70 EPS for the quarter, beating the consensus estimate of $2.61 by $0.09. Gilead Sciences had a return on equity of 92.36% and a net margin of 44.43%. The business had revenue of $7.30 billion for the quarter, compared to the consensus estimate of $7.16 billion. During the same period last year, the business posted $3.32 EPS. The company’s revenue was down 13.9% compared to the same quarter last year. On average, equities research analysts predict that Gilead Sciences will post $8.57 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 30th. Investors of record on Thursday, March 16th will be given a dividend of $0.52 per share. The ex-dividend date of this dividend is Tuesday, March 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.98%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.47. Gilead Sciences’s dividend payout ratio (DPR) is presently 18.91%.

This piece of content was first reported by sleekmoney and is owned by of sleekmoney. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece of content can be accessed at http://sleekmoney.com/gilead-sciences-inc-gild-stock-rating-reaffirmed-by-berenberg-bank/1659834.html.

In related news, Director John W. Madigan sold 105,000 shares of the stock in a transaction that occurred on Friday, November 18th. The shares were sold at an average price of $74.86, for a total transaction of $7,860,300.00. Following the completion of the transaction, the director now owns 121,761 shares of the company’s stock, valued at approximately $9,115,028.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John C. Martin sold 73,337 shares of the stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $73.59, for a total transaction of $5,396,869.83. Following the transaction, the insider now directly owns 3,204,433 shares of the company’s stock, valued at approximately $235,814,224.47. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. Van Hulzen Asset Management LLC boosted its position in Gilead Sciences by 9.1% in the second quarter. Van Hulzen Asset Management LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 100 shares during the last quarter. Penserra Capital Management LLC boosted its position in shares of Gilead Sciences by 148.3% in the third quarter. Penserra Capital Management LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 774 shares in the last quarter. Gemmer Asset Management LLC boosted its position in shares of Gilead Sciences by 15.5% in the third quarter. Gemmer Asset Management LLC now owns 1,301 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 175 shares in the last quarter. Lombard Odier Transatlantic Limited Partnership boosted its position in shares of Gilead Sciences by 55.6% in the third quarter. Lombard Odier Transatlantic Limited Partnership now owns 1,400 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 500 shares in the last quarter. Finally, Roble Belko & Company Inc boosted its position in shares of Gilead Sciences by 19.9% in the third quarter. Roble Belko & Company Inc now owns 1,605 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 266 shares in the last quarter. 74.19% of the stock is owned by hedge funds and other institutional investors.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

5 Day Chart for NASDAQ:GILD

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/gilead-sciences-inc-gild-stock-rating-reaffirmed-by-berenberg-bank/1659834.html

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *